Co-Authors
This is a "connection" page, showing publications co-authored by Fabio Ciceri and John Lambris.
Connection Strength
0.888
-
Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy. Clin Immunol. 2020 11; 220:108598.
Score: 0.226
-
Author Correction: Complement as a target in COVID-19? Nat Rev Immunol. 2020 07; 20(7):448.
Score: 0.223
-
The first case of COVID-19 treated with the complement C3 inhibitor AMY-101. Clin Immunol. 2020 06; 215:108450.
Score: 0.220
-
Complement as a target in COVID-19? Nat Rev Immunol. 2020 06; 20(6):343-344.
Score: 0.220